Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

OBJECTIVE: We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive weight loss compared with daily insulin glargine (IG) in patients with type 2 diabetes who were taking metformin alone or with sulfonylurea. This...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Guerci, Bruno, MacConell, Leigh, Haber, Harry, Scism-Bacon, Jamie, Trautmann, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Diabetes Association 2012
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308312/
https://ncbi.nlm.nih.gov/pubmed/22357185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1233
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller